$2.76
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Piper Sandler Upgrades Tvardi Therapeutics to Overweight From Neutral, Adjusts Price Target to $13 From $3
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Overview
52-week range
$2.75
$44
0% of range
Avg surprise (last 2)
-54.2%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
177%
EM ±40.6% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 8, 2026 | Mar/2026 | $-0.73 | $-0.65 | -12.3% | +77.3% | -0.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.59 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $1.00 | $-0.51 | -96.1% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-3.22 | — | — | — | +2.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.14 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-2.71 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-20.24 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.52 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.58 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.65 | $1.00 | -165.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-7M | — | $-6M | $-9M | $-4M | — | $-6M | $-7M |
| Net income | $-7M | — | $-6M | $4M | $-10M | — | $-6M | $-7M |
| EPS (diluted) | $-0.73 | — | $-0.59 | $-1.00 | $-3.72 | — | $-2.14 | $-2.71 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $20M | $21M | $21M | $21M | $34M | $32M | $37M | $49M |
| Inventory | — | — | — | — | $900,000 | $900,000 | $625,000 | $2M |
| Total current assets | $25M | $32M | $38M | $43M | — | $32M | $48M | $64M |
| Total assets | $26M | $32M | $39M | $44M | $39M | $35M | $51M | $72M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $11M | $11M | $11M | $11M | $47M | $41M | $51M | $61M |
| Total equity | $15M | $21M | $28M | $33M | $-101M | $-91M | $-79M | $-73M |